Granulomatous Mastitis Current Approach and Treatment

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-12-31

Study Completion Date

2018-01-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to retrospectively review the granulomatous mastitis and evaluated current approach and treatment.

HYPOTHESIS Although there is no common protocol for the treatment and management process of GM, the ternary treatment (medical treatment following by surgical procedure, Steroid+Antibiotic and surgical procedure, respectively) is considered as the most successful treatment approach.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Medical and Surgical Treatment for Idiopathic Granulomatous Mastitis

NCT02959580

Granulomatous Mastitis

UNKNOWN PHASE4

Effect of Different Surgical Approaches of Granulomatous Mastitis

NCT06712524

Breast-conserving Plastic Surgery Granulomatous Mastitis

RECRUITING NA

Idiopathic Granulomatous Mastitis Combination Therapy

NCT05361629

Idiopathic Granulomatous Mastitis

UNKNOWN NA

Could Intralesional Steroid be the Novel Treatment for Granulomatous Mastitis?

NCT04596046

Granulomatous Mastitis

COMPLETED NA

Local Steroid Treatment for Idiopathic Granulomatous Mastitis (LSTIGM)

NCT03766997

Granulomatous Mastitis

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

INTRODUCTION Granulomatous mastitis (GM) is a rare inflammatory disease of the breast which generally affects young parous women. It was emphasized that lactation and using oral contraceptive are considered among the predisposing factors of the disease. GM is firstly identified in 1972, and it is considered as an important disease because it is a great mimicker of breast carcinoma.

The form of treatments involves corticosteroids, antibiotics and general surgical resections including mastectomy. Furthermore, a preferred form of treatment has not been defined yet. Also, there are not enough data showing the results of using antibiotics. Since GM is a rare disease, there is no common consensus for the diagnosis and treatment of GM. The uncertainties about the distinct diagnosis, determining the form and term of treatment, the order of treatment if necessary, as well as what medical specialties need to involve in the treatment process still remain. Therefore, all these uncertainties cause a difficulty to manage the treatment process by physicians. Furthermore, since there is no enough study on GM and only limited case reports was presented in the literature, the success of treatment process is associated with the experience of treatment center. Therefore, there is a clear need for multicentric study that compares different approaches of the treatment process with the enough number of cases.

DATA COLLECTION In this study, patient's data will be retrospectively obtained by recording the data in patients' files and electronic records. The data includes the determined parameters by the study group of GM and the data will be recorded in an excel file that includes specific columns of the following entries: patients' age, diagnosis, secondary disease, diagnosis methods, treatments, recurrence, the risk factors that may cause the disease (smoking, using oral contraceptive, breast infection etc.). A shared excel file at the following website http://sanko.edu.tr/GranulamatozMastit has been created to record the data simultaneously. Each researcher can add the data at the file by using username and password. After data collection, the data will be presented mean+StDv. Statistical analysis will include Mann-Whitney U test, student's t test and chi-square test and statistical significance will set at P\< 0.05. The treatment group in this study will be divided as medical, surgical and medical+surgical and the comparison among these groups will be conducted to reach the aims determined in expected outcomes section. The sample size and power analysis were conducted and the results indicated that at least 100 samples in each group are required to achieve the statistical significance at P\< 0.05 with 90% power. The estimated total cases are expected over 400 cases.

EXPECTED OUTCOMES

1. Potential etiologies will be investigated.
2. The results will shed light on the optimal management method for patients with GM.
3. The treatment duration and order will be revealed.
4. Treatment and management algorithm will be created.
5. The hypothesis on the success of ternary treatment approach will be tested.
6. Creation of a prognostic index for GM will be tried.
7. Since a multicentric study is planned, experiences and results from different centers will be investigated.
8. Since the study will be multicentric with enough number of cases, the true statistical results will be obtained.
9. Among which medical specialties should be involved in communication during the determination of diagnosis and treatment will be revealed.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Granulomatous, Mastitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

medical treatment

In this study, patient's data will be retrospectively obtained by recording the data in patients' files and electronic records. The data includes the determined parameters by the study group of GM and the data will be recorded in an excel file that includes specific columns of the following entries: patients' age, diagnosis, secondary disease, diagnosis methods, treatments, recurrence, the risk factors that may cause the disease (smoking, using oral contraceptive, breast infection etc.). antibiotic, immunosuppressive drugs, methotrexate

No interventions assigned to this group